Google reviews landing pages; it doesn't review phone calls. For peptide and research-chemical brands, that gap is a legitimate reason to build call assets into the media plan — but only if you understand exactly what they can and can't shield you from.
Every disapproval a peptide brand gets from Google Ads traces back to the same surface: the landing page. Automated crawlers scan it. Human reviewers sample it. Both are looking for the same things — dosing language, treatment claims, checkout flows that look like they're selling a drug rather than a "research compound." A phone call has none of that surface area. Nobody at Google reads a transcript of the conversation your sales rep has with a lead before approving your campaign. That asymmetry is the entire argument for building call assets into a peptide media plan, and it's one most agencies in this space either don't understand or get the terminology wrong on.
Before going further, a correction that matters: if you've read that "call-only campaigns" are how you do this in 2026, that information is stale in two different ways. Standalone call-only campaigns as a dedicated campaign subtype were folded into the standard Search campaign structure years ago. And as of February 2026, Google shut off the ability to create new call ads — the specific call-only ad format inside standard campaigns — entirely, with existing call ads scheduled to stop serving in February 2027. If your account is still running on that format, you're on a clock. The current, correct mechanism is call assets attached to responsive search ads, plus a separate, still-active campaign type called call campaigns for brands that want a mobile-only, call-first structure. Understanding the difference between these three things — and which one your account is actually running — is step one.
People searching "call-only ads" or "call ads for peptide brands" are almost always looking for one of three distinct Google Ads mechanics. Getting them confused leads to broken setups.
Call assets attach a phone number and a clickable call button to a standard responsive search ad. On mobile, the button sits beneath the ad copy; on desktop, it shows as a "Call us" option. The person searching sees your headlines and description exactly like any other search ad — but they now have two paths forward: click through to the landing page, or tap to call. Both are billed as standard CPC. Call assets work on Search campaigns and Smart campaigns, and — this is the nuance most people miss — Performance Max does not support manually-added call assets the same way Search does. PMax exposes call functionality mainly through automated location assets, which is a meaningfully more automated, less controllable version of the same idea. If your call strategy depends on precise control over when and how the phone number shows, that control lives in Search campaigns, not PMax. We go deeper on where PMax's automation helps and hurts peptide accounts in our breakdown of Performance Max for peptide brands.
Call campaigns are a distinct, currently-supported campaign type built specifically to drive calls — mobile-only, bid-for-calls, no requirement to send traffic anywhere else. This is the closest living relative to what old-school advertisers remember as "call-only," and it is not being deprecated. It's a legitimate option when a brand wants a genuinely call-first campaign structure rather than a hybrid one.
This was the specific ad format that showed only a call button with no path to a website. Google stopped allowing new call ads in February 2026 and will stop serving existing ones in February 2027. If an agency pitches you on setting these up today, that's a red flag about how current their playbook is.
For most peptide brands, the right build in 2026 is call assets layered onto standard Search campaigns running compliant RSAs — giving searchers the choice between a call and a click — supplemented by a dedicated call campaign for keyword clusters where you specifically want to suppress the landing-page path.
Google's ad review process operates on two systems working together: an automated scanner that checks ad text, landing page content, and destination URLs against policy, and a human review layer that samples accounts — especially in flagged categories like health, supplements, and anything adjacent to pharmaceuticals — for closer inspection. Both systems are reading content you published. The ad copy. The landing page. The product page copy, the checkout flow, the disclaimers (or absence of them). This is the surface we audit constantly when building compliant peptide landing pages, because it's the single biggest source of disapprovals and account-level suspensions in this vertical.
A phone call isn't published content. Google doesn't dial your sales line, doesn't transcribe the conversation, and doesn't run NLP against what your rep says about dosing protocols, use cases, or research applications. The review stops at the ad and the call button. What happens after someone taps "call" is a live, human, unindexed conversation — structurally outside the thing Google's compliance systems are built to inspect.
This is a genuinely useful asymmetry, but it is not a loophole in the sense of "say anything on the phone." Advertiser identity verification, business operation checks, and category-level policy (LegitScript-style certification requirements that apply to supplement and research chemical categories in some markets) still attach to the account itself, not just the ad. What a call avoids is the automated content-scanning layer — not the underlying advertiser policy layer.
Peptide and research-chemical accounts get flagged for a narrow, predictable set of reasons: language that implies human consumption or medical treatment rather than research use, specific peptide names Google's classifiers associate with weight-loss or performance drugs (semaglutide-adjacent compounds, BPC-157, and similar are frequent triggers), dosing instructions, and checkout flows that read more like a pharmacy than a research supplier. Every one of those triggers lives on the landing page or in the ad copy — never in a phone call.
Red flag pattern: An ad claims "fast weight loss" and links to a landing page with a dosing calculator and before/after testimonials. That page gets scanned, flagged, and the whole account risks suspension — a single landing page can take down every campaign attached to it.
Better pattern: The ad copy stays within Google's health-and-medicine policy boundaries (research framing, no treatment claims — see our framework for writing compliant peptide ad copy for the specific language that clears review), and a call asset sits alongside it. The searcher who wants detail on protocols, comparisons, or "does this work for X" calls in and gets that from a live person instead of from a page that would have to state it in writing to satisfy the same demand. The landing page itself gets shorter, cleaner, and lower-risk — because it no longer has to carry the entire sales conversation on its own.
The mechanism isn't "hide the risky content from Google." It's "move the risky conversation off a surface Google reviews and onto one it doesn't," while keeping the ad and landing page themselves clean enough to pass review on their own merits regardless.
A call asset bolted onto an existing campaign without the surrounding infrastructure just adds a button nobody answers correctly. Here's the setup we run for peptide accounts:
This isn't a universal fix, and treating it like one creates its own problems.
Volume ceiling. Phone conversion has a hard staffing constraint that a landing page doesn't. A page converts at 2am with nobody watching; a call button unanswered is a lost lead and a bad signal. If your call volume outpaces your team's ability to answer promptly and knowledgeably, you're better off protecting a smaller share of traffic for calls and sending the rest to a page.
Desktop and non-call intent. A meaningful share of B2B and repeat-buyer research traffic never wants to call — they want to compare specs, read a page, and self-serve. Over-indexing on calls loses that segment. This is also where remarketing does the work call assets can't: for visitors who researched but didn't convert on either path, a structured remarketing strategy recaptures intent that a call button alone would simply drop.
Advertiser-level policy still applies. Business verification, certification requirements in regulated categories, and account-level enforcement based on patterns Google detects across your whole footprint don't disappear because one ad format routes to a phone instead of a page. A call button reduces content-review exposure; it does not exempt the business from advertiser policy.
It's not a substitute for a compliant page — it's a complement to one. Brands that use call assets as an excuse to run a landing page that would fail review on its own are one algorithm update or manual review sample away from the exact suspension they were trying to avoid. The account-wide risk from a single non-compliant page doesn't go away just because some traffic bypasses it.
Call quality varies by who answers. A well-trained rep converts a warm call at a rate a landing page can't match. An undertrained one loses leads a landing page would have quietly converted through a form. This format shifts risk and effort from your copywriter to your phone team — plan the investment accordingly.
We build call assets into peptide accounts as one lever among several, not as the whole strategy. The accounts that perform best pair a lean, policy-clean landing page with call assets on the highest-intent keyword clusters — the searches where someone is close to buying and has questions a static page can't safely answer without tripping a review flag. That combination is part of what we rebuilt for a client in our recovery peptide case study, where restructuring the call-to-click ratio across campaign types was one of the changes that moved both compliance stability and cost-per-acquisition in the right direction at the same time.
This is the kind of structural decision — which conversion path carries which kind of intent, and which one carries which kind of risk — that's hard to get right without having run Google Ads accounts through actual policy enforcement in this category repeatedly. We've built the media plans, taken the suspensions, appealed them, and rebuilt the accounts enough times to know which levers genuinely reduce exposure and which just move the same risk to a different tab.
Get a free 30-minute audit of your Google Ads or Meta Ads account. We’ll review compliance, structure, and growth opportunities — no strings attached.
Book a Free Audit